Entera Bio Ltd. (ENTX) stock
ENTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.00−0.02 (-0.66%)
Close on Nov 17, 2026Market cap $519.43MP/E –Yield –
Entera Bio price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Entera Bio's price to sales ratio was 393.1× on Jul 31, 2025, against 92.8× a year earlier. Over the last 5 years it ranged from 49.0× to 465.6×, with a median of 128.5×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2025 | Jul 31, 2025 | 393.1× | +46.9 |
| 2023 | Jul 31, 2023 | 346.2× | +272.4 |
| 2022 | Dec 30, 2022 | 73.8× | −144.4 |
| 2021 | Dec 31, 2021 | 218.2× | +134.7 |
| 2020 | Dec 31, 2020 | 83.4× | +34.4 |
| 2019 | Dec 31, 2019 | 49.0× | – |
See a number that looks wrong?